| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H13N5O4 |
| Molecular Weight | 243.2199 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)C1=NN(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O
InChI
InChIKey=NHKZSTHOYNWEEZ-AFCXAGJDSA-N
InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1
| Molecular Formula | C8H13N5O4 |
| Molecular Weight | 243.2199 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Taribavirin, an oral prodrug of ribavirin that was developed as nucleoside antimetabolite, which interferes with duplication of viral genetic material. Taribavirin was studied in phase III clinical trial for the treatment of chronic hepatitis C patients. However, this drug not yet approved for pharmaceutical use.
